The cost-effectiveness of Herceptin® in adjuvant setting:: The HerA trial

被引：0
|
作者：
Neyt, M
Cocquyt, V
Albrecht, J
机构：
[1] State Univ Ghent, B-9000 Ghent, Belgium
[2] State Univ Ghent Hosp, B-9000 Ghent, Belgium
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62915-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [1] Cardiac side effects in the HERceptin Adjuvant (HERA) trial
    Suter, T. M.
    Procter, M.
    van Veldhuisen, D. J.
    Muscholl, M.
    Muehlbauer, S.
    Gelber, R. D.
    Piccart-Gebhart, M. J.
    BREAST, 2007, 16 : S44 - S44
  • [2] Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
    Dedes, K. J.
    Szucs, T. D.
    Imesch, P.
    Fedier, A.
    Fehr, M. K.
    Fink, D.
    ANNALS OF ONCOLOGY, 2007, 18 (09) : 1493 - 1499
  • [3] Herceptin adjuvant (HERA) trial study, B-31- and N9831-study
    Nitschmann, S.
    INTERNIST, 2006, 47 (11): : 1183 - 1185
  • [4] The Cost-Effectiveness of rFVIIIFc in a Swedish Setting
    Schlueter, M.
    Henry, N.
    Jovanovic, J.
    Lowin, J.
    Krishnan, S.
    Myren, K. -J.
    HAEMOPHILIA, 2016, 22 : 75 - 75
  • [5] Moving forward:: Herceptin® in the adjuvant setting
    Tan-Chiu, E
    Piccart, M
    ONCOLOGY, 2002, 63 : 57 - 63
  • [6] Cost-effectiveness of adjuvant whole breast irradiation
    Ezendu, Kyrian
    Ali, Askal
    Diaby, Vakaramoko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 295 - 296
  • [7] Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
    Seferina, Shanly C.
    Ramaekers, Bram L. T.
    de Boer, Maaike
    Dercksen, M. Wouter
    van den Berkmortel, Franchette
    van Kampen, Roel J. W.
    de Wouw, Agnes J. van
    Voogd, Adri C.
    Heijnen, Vivianne C. G. Tjan
    Joore, Manuela A.
    ONCOTARGET, 2017, 8 (45) : 79223 - 79233
  • [8] Herceptin adjuvant (HERA) trial study, B-31- and N9831-study - Commentary
    Mallmann, P.
    INTERNIST, 2006, 47 (11): : 1185 - 1185
  • [9] Cost-effectiveness of TAC versus FAC for the treatment of node positive breast cancer in the adjuvant setting
    Fonseca, M.
    Araujo, G.
    Saad, E.
    Uehara, R.
    VALUE IN HEALTH, 2006, 9 (06) : A288 - A288
  • [10] Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial
    Procter, Marion
    Suter, Thomas M.
    de Azambuja, Evandro
    Dafni, Urania
    van Dooren, Veerle
    Muehlbauer, Susanne
    Climent, Miguel Angel
    Rechberger, Ernst
    Liu, Walter Tsang-Wu
    Toi, Mazakasu
    Coombes, R. Charles
    Dodwell, David
    Pagani, Olivia
    Madrid, Jorge
    Hall, Marcia
    Chen, Shin-Cheh
    Focan, Christian
    Muschol, Michael
    van Veldhuisen, Dirk J.
    Piccart-Gebhart, Martine J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : 3422 - 3428
12345